<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643106</url>
  </required_header>
  <id_info>
    <org_study_id>2008-059-1147</org_study_id>
    <nct_id>NCT04643106</nct_id>
  </id_info>
  <brief_title>Comparison of Hemostatic Agent to Suture in Terms of Hemostatic Function and Preservation of Ovarian Function</brief_title>
  <acronym>PRAHA-2</acronym>
  <official_title>A Multi-center, Randomized, Investigator-initiated Trial to Evaluate the Efficacy of PRreservation of ovArian Function, Hemostasis, and sAfety of a Hemostatic Agent Versus Suturing During Laparoscopic Ovarian Cystectomy for Endometrioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy of preservation of ovarian function, hemostasis, and&#xD;
      safety of a hemostatic agent versus suturing during laparoscopic ovarian cystectomy for&#xD;
      ovarian endometriosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In women with endometrioma who plan to undergo laparoscopic ovarian cystectomy, surgical&#xD;
      technique can influence postoperative ovarian function because of removal of normal ovarian&#xD;
      tissue with ovarian cyst and damage to ovarian tissue during bleeding control after stripping&#xD;
      of endometrioma. This study is designed to compare hemostatic sealant to suturing in terms of&#xD;
      hemostatic function, safety and preservation of ovarian function.&#xD;
&#xD;
      Ovarian function of all patients will be evaluated on pre op, post op 12 weeks, post op 48&#xD;
      weeks by measuring AMH and ovarian volume. And Hemostatic function will be evaluated by&#xD;
      measuring serum hemoglobin, blood loss during operation, etc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovarian function preservation 12 weeks after surgery</measure>
    <time_frame>12 weeks after surgery</time_frame>
    <description>Reduction rate of AMH level in serum 12 weeks after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian function preservation 48 weeks after surgery</measure>
    <time_frame>48 weeks after surgery</time_frame>
    <description>Reduction rate of AMH level in serum 48 weeks after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time required to finish hemostasis</measure>
    <time_frame>during operation</time_frame>
    <description>Stop-watch will be operated right after finishing stripping endometrioma. It will be evaluated how long the time have been spent for bleeding control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the success rate of hemostasis within 10 minutes</measure>
    <time_frame>during operation</time_frame>
    <description>Stop-watch will be operated right after finishing stripping endometrioma. It will be evaluated whether hemostasis is finished within 10 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss during operation</measure>
    <time_frame>during operation</time_frame>
    <description>The volume of blood loss will be estimated by using simple visual assessment technique referring to gauze count and irrigation bottle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>post-op 2 days, 12 weeks and 48 weeks</time_frame>
    <description>Change of serum hemoglobin from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion during admission</measure>
    <time_frame>post-op 2 days</time_frame>
    <description>whether patients are transfused during admission period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events associated with operation, bleeding or transfusion</measure>
    <time_frame>post-op 2 days</time_frame>
    <description>any adverse events during admission period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization period</measure>
    <time_frame>within post-op 2 weeks</time_frame>
    <description>days from admission day to discharge day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation running time</measure>
    <time_frame>during operation</time_frame>
    <description>time from anesthesia start to delivery of patient to recovery room</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Benign Ovarian Cyst</condition>
  <arm_group>
    <arm_group_label>Hemostatic agent group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL® Fibrin Sealant, Ethicon, USA), which consist of thrombin and coagulating proteins, mainly fibrinogen and fibronectin. If hemostasis is not fulfilled enough by using it, a additional intervention such as electrocoagulation with bipolar forceps and barbed suture is required to stop bleeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suturing group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During operation, barbed suture will be applied to the inner surface of ovarian parenchyme where ovarian endometriosis was attached. In this group, if bleeding is continued after suturing, additional electrocoagulation with bipolar forceps will be conducted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy</intervention_name>
    <description>During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®)</description>
    <arm_group_label>Hemostatic agent group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>suturing with barbed sutures during laparoscopic ovarian cystectomy</intervention_name>
    <description>During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding</description>
    <arm_group_label>Suturing group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
          -  Age: 19-45 year-old women&#xD;
&#xD;
          -  American Society of Anesthesiologists Physical Status classification 1 or 2&#xD;
&#xD;
          -  Plan of laparoscopic ovarian cystectomy for unilateral or bilateral ovarian&#xD;
             endometriosis diagnosed by ultrasonography&#xD;
&#xD;
          -  Regular menstruation every 21-45 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No 'ovarian' endometriosis&#xD;
&#xD;
          -  Suspicious disease of ovarian malignancy&#xD;
&#xD;
          -  Age: 18 and younger, 46 and older&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Lower than 0.05 ng/ml of serum Anti-mullerian hormone level&#xD;
&#xD;
          -  Hormonal therapy within recent 3 months&#xD;
&#xD;
          -  Considered as inappropriate by the researcher's judgment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee seung Kim, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyunji Lim, MD</last_name>
    <phone>82-2-2072-2821</phone>
    <email>hyunji3292@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hee seung Kim, MD/PhD</last_name>
    <phone>82-2-2072-4863</phone>
    <email>bboddi0311@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi</state>
        <zip>10326</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ga Won Yim, MD/PhD</last_name>
      <phone>82-31-961-7366</phone>
      <email>gawonyim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chae Hyeong Lee, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyunji Lim, MD</last_name>
      <phone>82-2-2072-2643</phone>
      <email>hyunji3292@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hee Seung Kim, MD/PhD</last_name>
      <phone>82-2-2072-4863</phone>
      <email>bboddi0311@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hee Seung Kim, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hee Seung Kim</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>endometrioma</keyword>
  <keyword>ovarian cystectomy</keyword>
  <keyword>ovarian function</keyword>
  <keyword>ovarian reserve</keyword>
  <keyword>hemostatic agent</keyword>
  <keyword>suture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Cysts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

